Ferring bolsters global gene therapy supply chain with European manufacturing facility
in PRESS RELEASE 2024 on
…
0
0
-
Read more
-
Ferring demonstrates effectiveness of a treat-to-target approach in mild-to-moderate ulcerative colitis in first major study
in PRESS RELEASE 2024 onRead moreFerring demonstrates effectiveness of a treat-to-target approach in mild-to-moderate ulcerative colitis in…
-
Dr. Michael Rosenblatt joins Ferring Pharmaceuticals’ Board of Directors
in PRESS RELEASE 2024 onRead more -
Ferring Pharmaceuticals successfully launches its third Swiss Franc Bond offering for CHF 330 million
in PRESS RELEASE 2024 onRead moreAd hoc announcement pursuant to Art. 53 LR Ferring Pharmaceuticals successfully launches…
-
Ferring announces results demonstrating the efficacy and safety of follitropin delta for women undergoing in vitro fertilisation using an agonist protocol
in PRESS RELEASE 2024 onRead moreFerring announces results demonstrating the efficacy and safety of follitropin delta for…
-
Ferring Pharmaceuticals and SK pharmteco enter into commercial gene therapy manufacturing deal
in PRESS RELEASE 2024 onRead moreFerring Pharmaceuticals and SK pharmteco enter into commercial gene therapy manufacturing deal…
-
Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring
in PRESS RELEASE 2024 onRead moreLaunch of two first-in-class medicines in 2023 marks start of exciting phase…
-
Ferring announces full availability of ADSTILADRIN® (nadofaragene firadenovec-vncg) in the U.S.
in PRESS RELEASE 2024 onRead more…